About Us

Committed to Improving Patients’ Life

Company Overview

Harbour BioMed is a global, clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics in the areas of oncology and immunological diseases to address unmet patient’s needs.

We are building a robust pipeline with our integrated Harbour antibody platform, that enable us to develop highly differentiated antibodies against various disease targets with great potency and safety profiles. Our proprietary Harbour Mice^® generate fully human monoclonal antibodies in the classical two heavy and two light chain (H2L2) format, as well as heavy chain only (HCAb) format. Building upon our HCAb antibodies, the HCAb-based immune cell engagers (HBICE^®) are capable of delivering tumor killing effects unachievable by combination therapies. Integrated with our single B cell cloning platform, our antibody discovery engine is highly unique and efficient for development of next generation therapeutic antibodies.

Our Mission

Healthy life · Breakthrough Medicines

HBM’s efforts are driven by our vision of delivering “Healthy life · Breakthrough Medicines”. To realize this vision, we have been partnering with global academic institutions, biotechnology and pharmaceutical companies by leveraging our platforms. We have established a strong track record of portfolio includes strategically selected co-development clinical assets and internal innovative NextGen projects to address unmet patient’s need. We also provide technology licensing for our proprietary Harbour antibody technologies to accelerate the industry innovation on antibody therapeutics.

Corporate Strategy

Our strategic priorities are focused on driving global inventions of transformative next generation medicines powered by our proprietary technology platforms and data driven science.

Immunotherapies have been increasingly recognized as critical components of evolving treatment paradigms owing to the superior efficacy and safety profiles. However, the current standards of care in oncology and immunological diseases fall short owing to complexities of these multicomponent, multifactorial diseases, thereby limiting the response and outcomes in most patient populations.

With a strong patient-centric approach, we combine the power of Harbour Mice^® with other advanced technologies, like single B cell cloning, bispecific antibody, bioinformatics and translational research to generate and identify lead antibody candidates to treat diseases. Our highly efficient antibody discovery engine ensures sustainable innovation in order to develop a diversified and balanced pipeline of potentially first-in-class and/or best-in-class cutting-edge immunology and IO therapies, both independently, and through collaborations with global pharmaceutical and research institutions. Our HCAb and HBICE^® platforms allow us to design unique and novel formats of antibodies, including bi- and multi-specific antibodies, that aim to exponentially enhance the clinical efficacy and safety of these candidates which are unachievable by combination therapies. We aspire to lead the next wave of immunotherapies in oncology and immunology.

Our portfolio also consists of strategically selected, in-licensed and risk-mitigated clinical assets with near-term revenue potential targeting diseases with high unmet need.

Our History

2022

Announced Global Out-License Agreement with AstraZeneca for CLDN18.2xCD3 Bispecific Antibody HBM7022

PNAS Published Preclinical Results of Harbour BioMed’s Next-Generation Fully Human Heavy-chain Antibody Porustobart

Entered into a License and Collaboration Agreement with Moderna

Launched Nona Biosciences’ “Idea to IND” Preclinical Solutions Business to Accelerate Global Biotherapeutic Innovation

2021

Batoclimab (HBM9161) Received China CDE Breakthrough Therapy Designation

Tanfanercept (HBM9036) and Batoclimab (HBM9161) Entered Phase III Clinical Trial

2020

Harbour BioMed Listing Hong Kong Stock Exchange (HBM HOLDINGS-B 02142.HK)

HCAb-Based Immune Cell Engagers HBICE^® Launched

2019

The Next-Generation Anti-CTLA-4 Antibody HBM4003 Entered Clinical Trial

2018

Suzhou Innovation Center Launched

1^st Phase II Clinical Trial: Tanfanercept (HBM9036）

2017

Zhangjiang Innovation Center Launched

Oncology Pipeline Initiative: Anti-CTLA-4 Antibody HBM4003

Immunology Pipelines Initiative: Batoclimab (HBM9161) and Tanfanercept (HBM9036)

2016

Harbour BioMed Established

The Fully Human Antibody Platform H2L2 and Fully Human Heavy Chain Only Antibody Platform HCAb Launch

2022

2021

2020

2019

2018

2017

2016

Management Team

Jingsong Wang

MD, PhD
Founder, Chairman and Chief Executive Officer

Dr. Jingsong Wang, is our Principal Founder, Chairman and Chief Executive Officer. Prior to founding our company, Dr. Wang served as Head of China R&D and Head of Translational Medicine, Asia Pacific, at Sanofi. He is a former attending physician and clinical fellow at Harvard Medical School. Dr. Wang received his Ph.D. in Molecular Pharmacology from China Pharmaceutical University and has also completed a Molecular Immunology Research Fellowship at Dr. Laurie Glimcher ’s laboratory at the Harvard School of Public Health.

Weihao Xu

Chief Financial Officer and Chief Business Officer

Mr. Weihao Xu, is our Chief Financial Officer and Chief Business Officer. Before HBM, Mr. Xu served as Chief Finance Officer at Alphamab Oncology, CASI Pharmaceuticals, and 111 Inc. Prior to that, he was active in the investment industry, working as the Portfolio Manager for Matthews Asia and several other international investment institutions, where he was responsible for global equity investments.

Yiping Rong

PhD
Chief Scientific Officer

Dr. Yiping Rong, is our Chief Scientific Officer. Prior to joining Harbour BioMed, Dr. Rong served as Associate Director of Cancer Research at Sanofi Asia Pacific R&D Center. Prior to that, Dr. Rong was Group Leader of Translational Research in Janssen Discovery Center and Project Leader of Biologics Discovery in Roche R&D.

Xiaolu Tao

PhD
Chief Development Officer

Dr. Xiaolu Tao, is our Chief Development Officer. Prior to joining Harbour BioMed, Dr. Tao served as Head of Clinical Pharmacology & Bioassay at Cstone. Before moving back to China, Dr. Tao worked at BMS as Clinical Pharmacology Director in the therapeutic areas of immunology and oncology for multiple innovative products.

Humphrey Gardner

MD
Chief Medical Officer

Dr. Humphrey Gardner is our Chief Medical Officer. Before joining Harbour BioMed, he served as Chief Medical Officer at Silicon Therapeutics and Chief of Medical Oncology at Evelo Biosciences. He also served critical leadership roles at Novartis, AstraZeneca and Biogen.

Danny Wu

General Manager for HBM China

Mr. Danny Wu, is our General Manager for HBM China. Prior to joining Harbour BioMed, he was Head of Marketing and Medical Affairs Department at Simcere Pharmaceutical. Prior to that, he served companies including MSD, Pfizer and Roche with roles in Sales and Marketing. During his tenure at MSD, he established ANA business unit.

Scientific Advisory Board

Frank Grosveld

PhD
Academy Professor of Cell Biology, Erasmus Medical Center, Rotterdam
Founding Chief Scientific Officer, Harbour BioMed

Frank Grosveld, Ph.D., has served on our scientific advisory board since December 2016. Dr. Grosveld is Co-founder and CSO of Harbour Antibodies and the inventor of Harbour Mice^®, Professor and former Head of Department of Cell Biology and Department of Clinical Genetics at Erasmus University Medical Center, Rotterdam, a fellow of Royal Society and a member of Royal Netherlands Academy of Arts and Sciences. Dr. Grosveld’s research on the control of globin gene expression has been selected as one of the top ten achievements of Medical Research Council (UK) (MRC) in the 20th century by Higher Education and Research Opportunities in the U.K. Dr. Grosveld was awarded the Louis-Jeantet Prize for Medicine in 1991, the Spinozapremie (Spinoza Prize) in 1995.

Robert Kamen

PhD
Entrepreneur in Residence, Venture Partner at Third Rock Ventures, Independent Non-Executive Director of Harbour BioMed

Robert Kamen, Ph.D., has served on our scientific advisory board since 2016. Dr. Kamen is a Venture Partner at Third Rock Ventures. In 2005, he co-founded BioAssets Development Corporation and served as its Chairman. He currently serves as an independent non-executive Director of the Company and a director of Jounce Therapeutics (NASDAQ:JNCE). He was previously a director of Neon Therapeutics and Harbour Antibodies. Earlier in his career, he was senior vice president of scientific affairs at the pioneering biotechnology firm named Genetics Institute, Inc.. Dr. Kamen received his bachelor ’s degree in biophysics from Amherst College, a Ph.D. in biochemistry and molecular biology from Harvard University Graduate School of Arts and Sciences. During his academic scientific career, he worked at the Imperial Cancer Research Fund.

Kenneth Murphy

MD, PhD
Eugene Opie First Centennial Professor of Pathology & Immunology, Washington University School of Medicine, Investigator, Howard Hughes Medical Institute, Member, US National Academy of Sciences

Kenneth Murphy, M.D., Ph.D., has served on our scientific advisory board since June 2019. Dr. Murphy is the Eugene Opie First Centennial Professor of Pathology & Immunology, Washington University School of Medicine in St. Louis, and a Member of the National Academy of Sciences. Dr. Murphy was awarded the William B. Coley Award for Distinguished Research in Basic Immunology by Cancer Research Institute in 2012 and the AAI-Thermo Fisher Meritorious Career Award by Thermo Fisher Scientific in 2016. Dr. Murphy received his bachelor degree in chemistry from Rice University and a Ph.D. in pharmacology and M.D. from Hopkins University School of Medicine.

Alexander Zukiwski

PhD
Chief Medical Officer,
CASI Pharmaceuticals

Alexander Zukiwski, Ph.D., has served on our scientific advisory board since May 2022. Dr. Zukiwski is currently Chief Medical Officer at CASI Pharmaceuticals. Prior to CASI Pharmaceuticals Dr. Zukiwski was Chief Executive Officer and Chief Medical Officer of Arno Therapeutics and had been a Director of Arno Therapeutics. Prior to Arno in 2007, Dr. Zukiwski served as Chief Medical Officer and Executive Vice President of Clinical Research at MedImmune. Prior to MedImmune, Dr. Zukiwski held several roles of increasing responsibility at Johnson & Johnson Pharmaceutical Research & Development LLC (J&JPRD) and Ortho Biotech. Dr. Zukiwski has more than 25 years of experience in global drug development and supported the clinical evaluation and registration of many successful oncology therapeutic agents, including Taxotere^®, Xeloda^®, Procrit^®/Eprex^®, Velcade^®, Yondelis^®, and Doxil^®. Dr. Zukiwski holds a bachelor’s degree in Pharmacy from the University of Alberta and a Doctor of Medicine degree from the University of Calgary. He conducted his post-graduate training at St. Thomas Hospital Medical Center in Akron, Ohio and the University of Texas MD Anderson Cancer Center.

Jon Wigginton

MD
Chief Medical Officer at Cullinan Oncology, Advisor at PMP Capital

Jon Wigginton, M.D., has served on our scientific advisory board since May 2020. Dr. Wigginton currently serves as Chief Medical Officer, Cullinan Oncology, and Advisor, MPM Capital. He previously served as Chief Medical Officer and Senior Vice President of Clinical Development at MacroGenics, Inc., a Maryland biotechnology company focused on immunotherapeutic approaches for cancer and autoimmune disease. Prior to MacroGenics, Dr. Wigginton served as Therapeutic Area Head of Immuno-Oncology, Early Clinical Research at Bristol-Myers Squibb (BMS), where he led the early clinical development of the BMS Immuno-Oncology portfolio including anti-PD-1, anti-PD-L1 and various immunotherapy combinations including anti-CTLA-4/anti-PD-1 among others. During his academic career, Dr. Wigginton held several positions at the National Cancer Institute, Center for Cancer Research (NCI-CCR), including Head of Investigational Biologics Section, Pediatric Oncology Branch, where he led an integrated basic, translational and early clinical research effort focused on combination immunotherapy. Dr. Wigginton also previously served as President of the Society for Immunotherapy of Cancer.

Robert Kramer

PhD
CSO of SalvaRx Therapeutics; BoD, Meditope Bioscience; Chair, NeoTx SAB; Member, Servier Pharma, Aro Biotherapeutics and Crown Biosciences SAB

Robert Kramer, Ph.D., has served on our scientific advisory board since December 2016. Dr. Kramer serves as CSO of Portage Biotech Inc. Dr. Kramer previously served as Vice President and Head of Discovery for Oncology Therapeutics at Janssen Research & Development, LLC (the Pharmaceutical Division of Johnson and Johnson), where he was responsible for leading Global Discovery, focusing on aberrant signaling cascades in tumor cells, as well as epigenetic reprogramming and tumor immunology using both small molecule and protein-based large molecule approaches. Prior to joining Janssen Research & Development, LLC, Dr. Kramer served as VP Drug Discovery and Research for Bristol-Myers Squibb (BMS), where he provided scientific leadership and strategic oversight for many pre-clinical Oncology and Immunology programs and projects that entered development. Dr. Kramer was previously an Assistant Professor at Harvard Medical School. Dr. Kramer received his Ph.D. in pharmacology from the University of Vermont and completed his post-doctoral fellowship in Oncology at the National Cancer Institute, National Institutes of Health.

Peter Moesta

PhD
Chief CMC Advisor at Harbour BioMed, Former CEO, Adello Biologics

Peter Moesta, Ph.D., has served on our scientific advisory board since December 2016. He oversaw the development, production and worldwide launch of important medicines, such as Humira, Yervoy and Opdivo. Dr. Moesta previously served in executive roles at Bristol-Myers Squibb.

Zhigang Tian

PhD
Member of Chinese Academy of Engineering, Member of Academia Europaea, Professor at University of Science and Technology of China (USTC), Director of Institute of Immunology of USTC, Director of The Key Lab of Innate Immunity and Chronic Diseases of Chinese Academy of Science, and President of the school of Basic Medicine

Zhigang Tian, Ph.D., has served on our scientific advisory board since August 2020. Dr. Tian is a member of Chinese Academy of Engineering, a member of Academia Europaea and a medical immunologist. Currently, he is a professor at University of Science and Technology of China (USTC), where he also works as a Director of Institute of Immunology, Director of The Key Lab of Innate Immunity and Chronic Diseases of Chinese Academy of Science, and President of the school of Basic Medicine, and the former dean of School of Life Sciences of USTC. Dr. Tian was awarded with The National Science Fund for Distinguished Young Scholars. He is the academic leader of Chang Jiang Scholars Program as well as the Innovation Research Program of National Natural Science Foundation of China. Dr. Tian is Head of National Science and Technology Major Project and Chief Scientist of National Major Research Plan Program.

Dr. Zhigang Tian’s laboratory is credited with seminal discoveries regarding basic knowledge and clinical study of natural killer (NK) cells, particularly liver-resident NK cells, cytokine-producing NK cells, and NK cell-based immunotherapy.